Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma.
Vogl DT et al. Clin Cancer Res. 2017 Jan 4. pii: clincanres.2526.2016. doi: 10.1158/1078-0432.CCR-16-2526. [Epub ahead of print].
Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).
Simões-Pires CA et al. Expert Opin Ther Pat. 2017 Jan 16. doi: 10.1080/13543776.2017.1282945. [Epub ahead of print].
Carfilzomib, lenalidomide, and dexamethasone in patients with heavily-pretreated multiple myeloma: A phase 1 study in Japan.
Suzuki K et al. Cancer Sci. 2017 Jan 16. doi: 10.1111/cas.13166. [Epub ahead of print].
A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma.
Jung SH et al. Oncotarget. 2017 Jan 10. doi: 10.18632/oncotarget.14582. [Epub ahead of print].
Peptide vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial.
Jørgensen NG et al. Stem Cell Investig. 2016 Dec 23;3:95. doi: 10.21037/sci.2016.11.09. eCollection 2016.
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer®, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: A phase IIa study.
Ludwig H et al. Leukemia. 2017 Jan 11. doi: 10.1038/leu.2017.5. [Epub ahead of print].
Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).
Touzeau C et al. Haematologica. 2017 Jan 5. pii: haematol.2016.160408. doi: 10.3324/haematol.2016.160408. [Epub ahead of print].
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.
Raje NS et al. Br J Haematol. 2016 Dec 22. doi: 10.1111/bjh.14483. [Epub ahead of print].